Navigation Links
Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
Date:9/24/2008

e unaware of their infection status and the large majority of individuals who know their condition do not currently receive drug therapy. There is also a growing number of individuals who have failed interferon-based regimens who may be successfully treated with combinations of two or more direct antivirals. It is expected that the next generation of therapies for treatment of HCV will include small molecules, such as ANA598, that directly act upon specific viral enzymes to inhibit viral replication. These new therapies are expected to improve overall therapy by increasing cure rates and potentially improving tolerability and convenience of treatment if doses of currently used agents can be reduced or eliminated.

About Anadys

Anadys Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. For the treatment of chronic hepatitis C, the Company is developing two potentially complementary agents, ANA598, a non-nucleoside polymerase inhibitor and ANA773, an oral TLR7 agonist prodrug. The Company is also developing ANA773 for the treatment of cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to (i) the expected timing and planned trial design of the ANA598 Phase Ib study, including Anadys' expectation that it will have viral load data from all three cohorts in the first quarter of 2009; (ii) predictions of future antiviral activity based on plasma drug concentrations seen in the healthy volunteer study and preclinical results to date; (iii) the potential for once-daily or twice-daily oral dosing and the belief that it should not be necessary to take ANA598 on an empty stomach in order to achieve desired plasma drug levels; (iv) the ability of Anadys to transition into Phase
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
2. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
5. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
6. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
7. Vion Pharmaceuticals Enters into Agreement to Conduct a Phase I/II Clinical Trial of Cloretazine(R) in Combination with Induction Therapy in Poor Prognosis AML Patients
8. Memory Pharmaceuticals and Roche Expand R3487/MEM 3454 Development Program
9. Oramed Pharmaceuticals Launches GLP1-Analog Program, Based on its Proprietary Drug Delivery Platform
10. Cadence Pharmaceuticals Updates Omigard(TM) Clinical Timeline
11. VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014  Australian drug delivery ... that it has raised A$19.3 million via a placement ... Europe , the U.S., Asia ... million from a share purchase plan (SPP) to be ... will be made in two tranches. "This ...
(Date:7/11/2014)... July 11, 2014 According to ... "Endoscopy Devices Market (Endoscopes, Endoscopic Operative Devices, and Visualization ... and Forecast, 2013-2019" the global endoscopy devices market was ... expected to grow at a CAGR of 6.8% from ... USD 36.9 billion in 2019. Browse the ...
(Date:7/11/2014)... , July 11, 2014  Veran Medical ... announced today the positive, cost-effective final results ... SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous biopsy ... percutaneous approach to biopsy when a traditional ... and physicians experience positive financial outcomes when ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Veran Medical Publishes Lung Cancer Patient Management Study 2
(Date:7/14/2014)... ATLANTA July 14, 2014 Physical fitness may buffer ... sitting, according to a new study by researchers from ... University of Texas. The study appears in the journal ... between prolonged sedentary time and obesity and blood markers ... taking fitness into account. , Sedentary behavior has been ...
(Date:7/14/2014)... Wisconsin (PRWEB) July 14, 2014 Secure ... software security, is partnering with the Software Assurance Marketplace ... to improve the software that drives everyday life. , ... institutions and housed in the Morgridge Institute for Research, ... S&T to advance software security practices by building a ...
(Date:7/14/2014)... Eye tests could be used to identify people in ... suggest. In one study, early results from 40 ... significant association between levels of beta-amyloid plaques in the ... in the brain. Beta-amyloid plaques in the brain are ... test could be used in conjunction with the brain ...
(Date:7/14/2014)... HealthDay Reporter MONDAY, July 14, ... to multiple health issues, but dementia isn,t one of them, ... may even delay dementia, the researchers found. "For those ... associated with a later age of developing full-blown dementia compared ... Woodruff. Woodruff, an assistant professor of neurology at ...
(Date:7/14/2014)... KeyPoint Credit Union is teaming up with ... and one-mile family fun walk. The run begins inside ... finishes inside Levi’s® Stadium. , Over the past five ... Mission City Community Fund. All proceeds benefit education, seniors ... athletes, part-time pavement-pounders and walkers are invited to help ...
Breaking Medicine News(10 mins):Health News:Physical fitness associated with less pronounced effect of sedentary behavior 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 2Health News:Madison-based SWAMP, Secure Decisions partner to enhance software security 3Health News:Eye Tests Might Help ID Alzheimer's, Studies Suggest 2Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 2Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 3
... 20 Conseco, Inc. (NYSE: CNO ),today ... rights plan,designed to protect stockholder value by preserving the ... operating loss carryforwards under,Section 382 of the Internal Revenue ... tax assets upon an "ownership change." The rights ...
... study found , , TUESDAY, Jan. 20 (HealthDay News) -- ... exercise, say U.S. researchers. , Dr. Jasmine Grewal, ... with abnormal diastolic function (when the heart is relaxed ... lower maximum capacity for exercise. The left ventricle is ...
... who purchased raw milk from the Conestoga Valley Dairy ... due to the risk of Salmonella contamination, Agriculture Secretary ... pasteurized to kill disease-causing bacteria or homogenized. Pennsylvania farms ... product samples tested in a laboratory due to the ...
... WASHINGTON, Jan. 20 While the U.S. Food and Drug ... affected by last week,s Peanut Corporation of America (PCA) recall ... that national brands of jarred peanut butter are not affected ... ingredients from PCA. , , In addition, ...
... Host Five Cancer Fighters on January 30th for a ... Lillians(TM), The Hippest Shoppe in Town(R) and the ... it will postpone "the dance," its annual fundraising event ... Oct. 23, 2009, at the Medina Entertainment Center.The annual ...
... entails lower risk, speedier recovery, researchers say , , TUESDAY, ... accessing and treating ailing hearts with angioplasty may be ... catheterization technique reduces risk, bleeding, cost and patient recovery ... year, about one million Americans undergo angioplasty to open ...
Cached Medicine News:Health News:Conseco Adopts Stockholder Rights Plan 2Health News:Conseco Adopts Stockholder Rights Plan 3Health News:Conseco Adopts Stockholder Rights Plan 4Health News:Conseco Adopts Stockholder Rights Plan 5Health News:Lillians(TM) Postpones 'The Dance' Fundraising Event; New Date Is October 23, 2009 2Health News:Angioplasty Via Wrist May Be Safer 2
MediNotes e is an EMR design which utilizes a "tab concept for navigation. MediNotes e can display multiple patients, encounter notes, workflow items, patient flow, messages, alerts, and more, all in...
... Pro Software developed a touchscreen EHR and ... While a user can choose to use ... to maintain eye contact while recording encounter ... Pro EHR also runs on a pen ...
... Anasazi Clinicians HomePage is a comprehensive on-line ... helps you by reducing your time and ... to concentrate on the clients quality of ... completes a chart audit and shows you ...
... The GE RecordsTFC System ... Registration and other patient/resident record ... approach. It supports multiple facilities ... outpatient and ambulatory clinics, community ...
Medicine Products: